Ischemic heart disease is the number one cause of mortality and morbidity in the Western world, and this unfortunate reality is unlikely to change in the future. In fact, it is believed that in 2020 acute coronary syndromes (ACS) will over-run infectious disease and cancer to become the leading cause of death and disability, not only in industrialized countries, but also in the developing world.
INTRODUCTION
Ischemic heart disease is the number one cause of mortality and morbidity in the Western world, and this unfortunate reality is unlikely to change in the future. In fact, it is believed that in 2020 acute coronary syndromes (ACS) will over-run infectious disease and cancer to become the leading cause of death and disability, not only in industrialized countries, but also in the developing world.
(1) However, despite these facts the diagnostic approach to ACS remains one of our most diffi cult and controversial challenges. (2) As our understanding of the pathobiology of atherothrombosis has improved, researchers have attempted to evaluate the activities of these biological processes by measuring markers in plasma or urine (i.e. biomarkers). Indeed, several conventional and promising new markers of myocardial injury have been identifi ed.
This overview focuses on established and emerging biomarkers and their role in the diagnosis, risk stratifi cation, and prognostication of patients presenting with ACS.
HISTORICAL BACKGROUND TO THE DIAGNOSIS OF ACUTE CORONARY SYNDROMES
In 1971, the World Health Organization (WHO) developed a defi nition of acute myocardial infarction (AMI), which requires the presence of 2 of the following 3 major criteria: chest pain suggestive of myocardial ischemia, electrocardiographic (ECG) manifestations and indicative laboratory changes. (3) This was a major innovation, and by the early 1990s the WHO defi nition had become a cornerstone in clinical and laboratory medicine.
Despite increasing focus on biochemical markers during the last 2 decades, the search for the optimal marker is ongoing. Early markers of AMI such as aspartate aminotransferase, lactate dehydrogenase and creatine kinase (CK), were non-specifi c and did not provide defi nitive proof of myocardial involvement. Assays to measure the enzymatic activity of the creatine kinase muscle brain isoenzyme (CK-MB) was an important advancement, especially in terms of improved specifi city. Pathologic fi ndings of an AMI
CRITERIA FOR BIOMARKER EVALUATION IN ACS
Morrow and De Lemos have proposed that evaluation of the clinical utility of new biomarkers requires at least 3 fundamental questions to be answered. (6) 1. Can the clinician measure the biomarker?
The biomarker must be easy to measure in a cost-effective manner, and not require specialized plasma collection techniques or assay techniques.
Available assays should be easily accessible and have a prompt turnaround time.
Does the biomarker add new information to the risk assessment?
It is important that the proposed biomarker provide information, which adds to or improves upon existing available tests. A strong and consistent association should exist between the biomarker and patients with ACS with respect to clinical outcome to allow for prognostic application of that marker.
3. Will the biomarker help the clinician to manage patients?
As outlined in Figure 1 , each biomarker has the potential to address different mechanisms in the pathobiology of plaque instability and, Several biomarkers meet these criteria, but only few are ready for clinical practice.
TROPONINS
Cardiac Troponin T and I are cardiac regulatory proteins that control the calcium-mediated interaction of actin and myosin. 
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level defi ned as abnormal be raised to that value at which a specifi c assay has a CV of 10 percent of less. (9) Currently, it is recommended that the cut-off (clinical discriminator) value of Troponin T or I used for the defi nition of AMI is 0.1 ng/mL according to ROC analysis. Elevations in cardiac troponins after AMI persist for up to 10 days, permitting late diagnosis. (12) In contrast, CK-MB elevations return to baseline levels by 36 to 48 hours and cannot be used for late diagnosis.
Use for diagnosis of AMI
Previously, new elevations in CK-MB were used to detect reinfarction.
Troponins can now be used for this purpose, bearing in mind that a 20% increase from prior levels is supportive for the detection of ongoing ischemia (Figure 3 ).
It is important to note that, while troponin measurement is a useful tool for the diagnosis of ACS, several limitations exist. Since troponin concentrations only begin to rise 2 to 3 hours after the onset of AMI, patients who present earlier will have negative troponin levels, thereby limiting the diagnostic capabilities of this biomarker. Certain patients with unstable angina present with acute chest pain and myocardial ischemia, and yet have negative troponin levels. It has been shown that these patients still have a high incidence (6-8%) of AMI at 30 days, even with the use of state of-the-art evidence-based therapy. (13) Similarly, a subset of patients with ACS may not develop necrosis despite severe coronary artery disease and myocardial ischemia. They clearly need further characterization and advice but escape scrutiny due to negative troponin results. Owing to their tissue specifi city, another limitation of troponins is their inability to discriminate between ischemic and nonischemic myocardial injury, such as traumatic injury, congestive heart failure, pericarditis, and myocarditis. Thus, if the Tn is normal and then becomes elevated, a new event rather than reinfarction has occurred. inhibitors, anti-platelet agents and low molecular-weight heparins. (9) Thus, the impact of a positive or negative troponin at presentation would seem to be central to the management decision. The degree of elevation of troponin also has signifi cant prognostic value, with the risk of death increasing proportionately with the absolute troponin level.
CK-MB ISOENZYME
Since CK is widely distributed in tissues, elevations in total serum CK lack specifi city for cardiac damage, and a consensus statement of the European Society of Cardiology and the America College of Cardiology concluded that total CK no longer has a role in diagnosing an AMI. Most assays for CK-MB measure CK-MB mass; such assays are more sensitive than active assays. Because CK-MB comprises a lower fraction in skeletal muscle than in the heart, percentage criteria (from 2.5 to 5 percent) have been proposed to distinguish skeletal muscle damage from cardiac damage. These criteria are not recommended, since they improve specifi city, but do so at the cost of sensitivity in patients who have both skeletal and cardiac injury. Typical criteria for the diagnosis of an AMI require a total CK elevation twofold above normal with a simultaneously elevated CK-MB. However, ischemic injury may occur in the presence of a normal total CK but elevated CK-MB. In a review of almost 26 000 patients with NSTEMI , the primary endpoint of death or AMI at 180 days was signifi cantly higher in patients with elevated CK-MB, independent of whether total CK was normal or elevated.
(17)
MYOGLOBIN
The ubiquitous heme protein myoglobin is elevated in roughly similar proportions as CK-MB and troponins among patients with AMI. (18) However, several limitations exist to the use of serum myoglobin for the diagnosis of AMI:
The rapid release and metabolism of myoglobin can result in an undulating pattern characterized by increases and decreases in serum myoglobin concentration that can lead to clinical confusion. (19) ■ Myoglobin also lacks specifi city for the heart and serum concentrations are elevated after injury to a variety of tissues, particularly skeletal muscle. Myoglobin levels are also increased following recent cocaine use and in patients with impaired renal function due to decreased clearance. (20) Because of these limitations and absence of any advantage over troponins, myoglobin should not be routinely measured in patients with suspected AMI.
HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP)
The acute phase reactant CRP is perhaps the best characterized of the currently available infl ammatory biomarkers. Clinically, CRP can be measured with several standardized, validated, and inexpensive highsensitivity assays. Trial Evaluating Rosuvastatin (JUPITER) study) is evaluating whether hsCRP-guided statin administration will have a favorable impact on cardiovascular disease. Thus, hsCRP may yet be proved to be a biomarker able to guide primary prevention studies.
B-TYPE NATRIURETIC PEPTIDES
Brain natriuretic peptide (BNP) and its N-terminal amino acid fragment (NT-proBNP) are neurohormones synthesized predominantly in the ventricles and released into the circulation in response to ventricular dilation and pressure overload. These peptides have been found to be useful in assisting with the diagnosis of congestive heart failure in dyspneic patients, with increasing levels correlating grossly with the severity of left ventricular dysfunction (LVD), both clinically and haemodynamically. (24) More recently, multiple large studies have shown BNP and NT-proBNP levels to be strong independent predictors of LVD and death in the months after both STEMI and NSTEMI. (25) It has ■
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also been demonstrated that NT-proBNP is able to defi ne not only myocardial necrosis, but also reversible ischemic changes in patients with ACS. (26) The mechanisms for the increase in NT-proBNP in patients with ACS and normal ejection fraction have not been precisely defi ned. It has been suggested that cardiac myocytes secrete natriuretic peptides during the prolonged ischemic phase that precedes cell death. (26) Therefore, ischemia may be an additional stimulus for NT-proBNP synthesis. (27) Furthermore, serial measurements of NT-proBNP may permit an ongoing assessment of risk in patients with ACS. Since this peptide is highest during the acute phase of presentation and then gradually falls over 6 months, elevated levels at any time period are associated with increased risk. (28) This biomarker rises rapidly during the fi rst 24 hours
following an AMI and may be considered as an additional marker in the diagnosis of AMI, especially in those without regional wall motion abnormalities on echocardiography. (29) Although B type natriuretic peptides are promising across the entire spectrum of ACS, they are still in the early stages of widespread clinical use. There is a pressing need to address several assay-related issues, their application to different ethnic groups, and fi nally the costeffectiveness of these peptides before they are used on a large-scale clinical and epidemiological basis.
OTHER NOVEL MARKERS
A variety of other biomarkers have been evaluated in the context of ACS, but none are available for routine clinical use.
Heart-type fatty acid binding protein (H-FABP) is a small cytosolic protein that behaves similarly to myoglobin in its kinetics and release. It is released into the circulation in response to myocardial injury, and may provide added value to other cardiac biomarkers for the early diagnosis of AMI. (30) The albumin cobalt binding test, which measures the concentration of ischemia-modifi ed albumin (IMA), has been recently proposed for early detection of myocardial ischemia without infarction. (31) The main limitation of IMA at present is its low specifi city, since the test is positive in many conditions like cancer, infections, end-stage renal disease, liver disease and brain ischemia. In addition, the need for adjustment for baseline albumin, and the frequent overlap between normal and abnormal values, renders this test diffi cult to interpret in many patients.
■ ■
The pregnancy-associated plasma protein-A (PAPP-A) is a zincbinding matrix metalloproteinase, which is expressed in eroded and ruptured atherosclerotic plaques. The PAPP-A level has been recently acknowledged as a strong predictor of cardiovascular events in patients with ACS. (32) Increasing evidence suggests that soluble CD40 ligand plays an important part in disease progression and plaque destabilization. (33) Soluble CD40 ligand, which is expressed on platelets and released from them on activation, has been found to be a powerful biomarker of infl ammatory thrombotic activity in patients with ACS. (34) Elevated levels of this biomarker can also identify patients with ACS who are at highest risk for cardiac events. Therefore, soluble CD40 ligand not only contributes to the pathophysiology of ACS but also represents a reliable and powerful clinical marker for use in identifying patients with high-risk atherosclerotic lesions, coronary thrombosis, or both. (35, 36) A promising new biomarker is growth differentiation factor 15 (GDF-15), a member of the growth factor beta cytokine superfamily. GDF-15 is released from myocardial cells after ischemia and reperfusion injury and has recently been shown that circulating levels are a strong independent marker of 1-year mortality in patients with acute coronary syndrome. (37) Several other markers of infl ammation, which may show clinical promise, include lipoprotein-associated phospholipase A2, also known as platelet-activating factor acetylhydrolase, (38) tumor necrosis factor alpha, (39) myeloperoxidase, (40) interleukin-6 and 8, and the leucocyte adhesion molecules ICAM-1, VCAM-1, and P-selectin.
CONCLUSIONS
Although this overview has focused on the role of several cardiac biomarkers in ACS, it is important to recognize that the fundamental issue with all markers is that there is no gold standard for the diagnosis of cardiac ischemia. Everyone is interested in fi nding the next biomarker that will be more specifi c and possibly cheaper than the current biomarkers in the diagnosis and risk stratifi cation of ACS. Perhaps, ongoing efforts in plasma-based biomarker research should concentrate on the use of a multimarker approach to enhance our diagnosis, prognostic assessment and management of patients with suspected ACS, as compared with using individual markers alone. It is recommended that current practice involve the selective use of biomarkers in patients in whom a more complete assessment of risk is desired. At present, routine biomarker measurement is not advocated until further data become available, which will support the benefi t of specifi c therapeutic interventions. 
